Suchergebnisse - "Hasselbalch, Hans Carl"

PubPharm (7)

1

JAK2V617F drives gut microbiota differences in patients with myeloproliferative neoplasms

enthalten in: European journal of haematology | 2024

von Eickhardt-Dalbøge, C. | Nielsen, H. | Fuursted, K. | +15

2

Pronounced gut microbiota signatures in patients with JAK2V617F-positive essential thrombocythemia

enthalten in: Microbiology spectrum | 2023

von Eickhardt-Dalbøge, C. | Ingham, A. | Nielsen, H. | +13

3

Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis

enthalten in: Cancer medicine | 2018

von Mikkelsen, S. | Kjaer, L. | Bjørn, M. | +14

4

Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib

enthalten in: Expert review of hematology | 2017

von Bjørn, M. | Hasselbalch, H.

5

Second malignancies in hydroxyurea and interferon-treated Philadelphia-negative myeloproliferative neoplasms

enthalten in: European journal of haematology | 2017

von Hansen, I. | Sørensen, A. | Hasselbalch, H.

6

Minimal residual disease after long-term interferon-alpha2 treatment : a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera

enthalten in: Leukemia & lymphoma | 2016

von Utke Rank, C. | Weis Bjerrum, O. | Larsen, T. | +4

7

Interferon in polycythemia vera and related neoplasms. Can it become the treatment of choice without a randomized trial?

enthalten in: Expert review of hematology | 2015

von Hasselbalch, H. | Silver, R.

1
[1]